Atwood & Palmer Inc. Acquires 2,576 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Atwood & Palmer Inc. grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 349,256 shares of the biopharmaceutical company’s stock after purchasing an additional 2,576 shares during the quarter. Gilead Sciences makes up approximately 2.2% of Atwood & Palmer Inc.’s investment portfolio, making the stock its 15th largest position. Atwood & Palmer Inc.’s holdings in Gilead Sciences were worth $32,261,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in the stock. Bellevue Group AG increased its position in shares of Gilead Sciences by 18.2% during the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after acquiring an additional 7,093 shares during the period. Quantinno Capital Management LP increased its holdings in Gilead Sciences by 149.5% during the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after purchasing an additional 48,910 shares during the period. Legal & General Group Plc raised its position in Gilead Sciences by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after purchasing an additional 93,068 shares in the last quarter. IRON Financial LLC purchased a new stake in shares of Gilead Sciences in the 3rd quarter worth $830,000. Finally, Capital Investment Advisors LLC grew its position in shares of Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock worth $35,793,000 after buying an additional 9,791 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 456,234 shares of company stock valued at $42,130,461. Corporate insiders own 0.29% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on GILD. Bank of America restated a “buy” rating and issued a $109.00 price target on shares of Gilead Sciences in a report on Tuesday, December 10th. Morgan Stanley raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $87.00 to $113.00 in a research note on Friday, January 10th. Truist Financial increased their target price on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research report on Friday, November 8th. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, BMO Capital Markets upped their price objective on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $97.96.

Gilead Sciences Stock Up 0.2 %

NASDAQ:GILD opened at $91.84 on Tuesday. The firm has a market capitalization of $114.46 billion, a P/E ratio of 1,020.44, a PEG ratio of 1.29 and a beta of 0.18. The company’s fifty day moving average price is $91.75 and its 200-day moving average price is $84.20. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period last year, the business earned $2.29 earnings per share. Gilead Sciences’s quarterly revenue was up 7.0% on a year-over-year basis. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.35%. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.